Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound

Pulmonary Hypertension Clinical Trial

Official title:

Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02243111
• Other study ID #: DOP22_1
• Status: Terminated
• Phase: N/A
• First received: September 8, 2014
• Last updated: January 20, 2016
• Start date: September 2014
• Est. completion date: December 2015

Study information

• Verified date: June 2014
• Source: Echosense Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e. the transthoracic parametric Doppler (TPD) (EchoSense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS signals that are related to pulmonary hypertension.

The TPD performance in detecting PAH in SSc patients will be assessed in the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: December 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able and willing to give signed informed consent prior to enrollment

2. Male or female, = 18 years of age

3. Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score = 9.

4. Patients with RHC data available from measurement within 3 weeks prior to TPD assessment

5. No change in or initiation of PAH specific therapy between the last RHC and TPD

Exclusion Criteria:

1. People unable or unwilling to give informed consent.

2. PCWP or LVEDP > 15 mmHg

3. Any PH etiology outside Group 1 (Dana Point, 2008)

4. Pregnant women

5. Patients having severe chest wall deformity

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension
• Scleroderma, Diffuse
• Scleroderma, Systemic
• Sclerosis
• Systemic Sclerosis

Intervention

Radiation:
• Doppler ultrasound
Detecting Doppler signals from the lungs on the right chest wall

Locations

Country	Name	City	State
Israel	Reumatology department, Rabin medical center	Petach Tikva

Sponsors (1)

Lead Sponsor	Collaborator
Echosense Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC.	Analyze Doppler data of 4 SSc groups(according to pulmonary hypertension sevirity ) resulting in typical features. The features will be implemented in a pre-determined diagnostic algorithm that will determine the overall statistical analysis success of the method in comparison to RHC data.	12 month	No